NeuroBo Pharmaceuticals, Inc. (NRBO)

0.6600 -0.0256 (-3.73%) As of 10:19AM EDT. Market open.

NeuroBo Pharmaceuticals, Inc.

200 Berkeley Street
Office 19th Floor
Boston, MA 02116
United States
857 702 9600
https://www.neurobopharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 5

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Joseph Hooker	Interim CEO & Pres	N/A	N/A	N/A
Dr. Matthew Bardin BCPS, Pharm.D.	Sr. VP of Operations	N/A	N/A	N/A

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company that develops and commercializes multimodal disease-modifying therapies for viral, neuropathic, and neurodegenerative diseases. It develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Corporate governance

NeuroBo Pharmaceuticals, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.